Clinical Trial Update: Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov entry describes a phase 2 trial evaluating icotinib as neoadjuvant and adjuvant therapy for EGFR-mutant stage IIIB or oligometastatic no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN